Crestline Management’s Epizyme, Inc EPZM Stock Holding History

Crestline Management’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-28,700	Closed	-$492K	–	176
2017 Q1	$492K	Buy	+28,700	New	+$382K	0.09%	85

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Crestline Management's EPZM Position: Q2 2017 in Review

Crestline Management sold out of Epizyme, Inc (EPZM) in Q2 2017, closing a stake of 28,700 shares — an estimated $492K sold.

Crestline Management first reported a position in EPZM in Q1 2017 and held it in 1 quarter. The position peaked at $492K in Q1 2017. 108 funds tracked by Wall St. Rank hold EPZM as of Q2 2017.

Crestline Management reported no remaining Epizyme, Inc position as of Q2 2017 after selling out during the quarter.
Crestline Management sold 28,700 Epizyme, Inc shares in Q2 2017, an estimated $492K.
Crestline Management first reported a position in Epizyme, Inc in Q1 2017 and held it in 1 quarter.
Crestline Management's Epizyme, Inc position peaked at $492K in Q1 2017.
108 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2017.

Based on Crestline Management's 13F filing for Q2 2017, filed 14 Aug 2017.